Becton Dickinson lifts profit view on strong surgical equipment demand
May 2 (Reuters) -Becton Dickinson BDX.N raised its annual profit forecast and beat second-quarter profit estimates on Thursday, as the group banks on strong demand for its surgical equipment and syringes.
Medical technology firms like Becton, Boston Scientific BSX.N and Abbott Laboratories ABT.N are benefiting from a boost in demand as more people, especially older patients, undergo surgeries that were put on hold during the pandemic.
The company's biggest unit, which makes devices to administer drugs, reported quarterly sales of $2.45 billion, in line with analysts' expectations, according to LSEG data.
Becton - one of the world's largest syringe suppliers - said in March it was increasing the production of medical syringes in the U.S. after the country's drug regulator recommended not using some China-made syringes as part of its quality probe.
The interventional unit that offers surgical and critical care devices recorded sales of $1.29 billion in the quarter, beating estimates of $1.19 billion.
The group's total revenue grew 4.6% from a year earlier to $5.05 billion, slightly above expectations of $5.04 billion.
On an adjusted basis, the New Jersey-based company expects to earn $12.95 to $13.15 per share in the 2024 fiscal year, up from its previous forecast of $12.82 to $13.06 per share.
Becton earned an adjusted profit of $3.17 per share in the second quarter through March 31, above analysts' estimates of $2.97 per share.
Reporting by Christy Santhosh in Bengaluru; Editing by Milla Nissi
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
